



# **Filovirus Animal Model Workshop**

## **Vaccine Development Panel Discussion**

**September 11, 2007**

Ed Nuzum, NIAID, Chair

Tom Ksiazek, CDC

Alan Schmaljohn, University of Maryland, Med. School

Tom Geisbert, NIAID

Nancy Sullivan, NIAID



# Questions

1. What is/are the most appropriate animal species to use as models for filoviruses?
2. Is there a specific strain, or isolate of virus(es) that should be used in animal studies and what challenge dose should be used if the goal is to protect against a potential bioterrorist release?
3. What challenge route/s should be used if the purpose is to develop a vaccine to protect against a bioterrorist attack?
4. What types of studies should be required to develop correlates of immunity/protection for filovirus vaccines in humans? Specifically, what immune responses should be examined in animals and what functional assays need to be established and validated?



# **Filovirus Animal Model Workshop**

## **Therapeutic Panel Discussion**

**September 12, 2007**

Robert Johnson, NIAID, Chair

Tony Sanchez, CDC

Sina Bavari, USAMRIID

Mike Bray, NIAID

Doug Reed, USAMRIID



# Questions

1. What are the similarities or differences in considering developing appropriate animal models for therapeutic countermeasures as compared to that for the vaccines?
2. What initial clinical symptoms should be focused on to identify potentially relevant ranges and triggers for timing of treatment initiation for development of therapeutic animal models?
3. What types of animal studies may contribute to assessment of antiviral interventions in a post-exposure situation, including approaches to assessment of post-exposure prophylaxis and approaches to assessment of treatment of established illness?
4. What are some of the different factors that may be relevant to interventions that focus on inhibition of viral replication as compared to interventions that focus on modification of host responses?
5. What approaches can be used to optimize information collection if outbreaks occur at various times during the development sequence for a candidate product?